

Management of Children with Sickle Cell Disease and/or Asplenia with Fever or Acute Illness Greater than 1 month old Outpatient Follow Up

K07002307 Jun/7/2002 M SCA,TEST Visit ER0000145/12 **HCN:** 22222222 Van den Hof, TEST / TEST, Maureen Dec/8/2012

Printed Surname

| Patient: | | | |
|---|------------------|---------------------|---------------------------------------|
| □Alert Record Reviewed □No Allergi | ies Known | | |
| □Allergies-Adverse Reactions-Cautions: _ | | | |
| Age Patient's Weight | kg | Date of Patient's W | Veight |
| DIAGNOSIS: | | | |
| Items preceded by a bullet (•) are active orders Refer to APPHON website for the link to the sickle cell disease in Canada (https://www.aprecedemons.org/line | CanHaem C | Consensus Statem | ent on the care of patients with |
| GENERAL | | | |
| BP, HR, RR Temp and pulse oximetry | | | |
| History and physical examination | | | |
| • Review all test results ordered in emerge | ency depart | tment | |
| LAB/INVESTIGATIONS | | | |
| Blood culture and sensitivity if temperatu | | er than or equal to | 38° C one hour apart or greater than |
| or equal to 38.3° C, or if patient appears | unwell | fragulana | |
| □CBCD [□Reticulocyte Count [| ⊒daily □daily | frequency | |
| □Na+, K†BUN, creatinine | ⊐ualiy □daily | frequency | |
| □ALT, AST, bilirubin (total and direct) | | | |
| □Blood gas, blood glucose, lactate if he | • | . , | |
| □NPA (PCR) for: □Influenza/RSV □Ex | | | val required) |
| COVID19 (if extended | | | , |
| ☐Throat swab for mycoplasma | | | |
| □Other | | | |
| MEDICATIONS | | | |
| ☐ If 18 to 24 hours after initial dose in el | | | |
| cefTRIAXone (100 mg/kg/dose, maxin | num 2000 r | mg/dose) | _mg IV/IM x 1 dose |
| ☐ If 12 to 18 hours after initial dose in e | mergency (| denartment/clinic | |
| cefTRIAXone (50 mg/kg/dose, maximu | | | |
| If blood culture is negative at 24 hours, a above. | | | <u> </u> |
| • For an identified source of infection (acu | ute otitis me | edia, streptococca | I pharyngitis, etc), oral antibiotics |
| may be used at the discretion and decis | | | |
| prescription. | | - | |
| In patients greater than 5 kg, the preferr | | | tution for IM injection is 1% |
| lidocaine without epinephrine as per IWI | K Drug Info | ormation Website) | |
| | | | |
| FOLLOW-UP/ASSESSMENT | | | |
| _ocation | | Date: | Time: |
| | | | |
| DATE (MONVIN TO (COLUMN) | | | <u> </u> |
| DATE (yyyy/MON/dd) Time (24hr/hh:mm) Prescri | ber Signature | 9 | Printed Surname/Registration # |

DATE (yyyy/MON/dd) Time (24hr/hh:mm) Verified By (Signature)